Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Cancer Management and Research
|
June 23, 2022
Outcomes of Patients with <i>EGFR-</i>Mutant Advanced NSCLC in a Developing Country in Southeast Asia
Soon Hin How, Chong Kin Liam, Muhammad Adil Zainal Abidin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Hidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
Cancer Discovery
|
March 6, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib
Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 13, 2023
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
Thanyanan Reungwetwattana, Byoung Chul Cho, Ki Hyeong Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
Byoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2023
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
The New England Journal of Medicine
|
September 9, 2025
Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC
James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
The New England Journal of Medicine
|
June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC
Byoung C Cho, Shun Lu, Enriqueta Felip, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Cancer Management and Research
|
June 23, 2022
Outcomes of Patients with <i>EGFR-</i>Mutant Advanced NSCLC in a Developing Country in Southeast Asia
Soon Hin How, Chong Kin Liam, Muhammad Adil Zainal Abidin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Hidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
Cancer Discovery
|
March 6, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib
Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 13, 2023
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
Thanyanan Reungwetwattana, Byoung Chul Cho, Ki Hyeong Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
Byoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2023
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
The New England Journal of Medicine
|
September 9, 2025
Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC
James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
The New England Journal of Medicine
|
June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC
Byoung C Cho, Shun Lu, Enriqueta Felip, et al.
Page
of 3